First-in-human single and multiple ascending dose study of BMS-986337 in healthy adults

Phase 1, randomised, double-blind trial of BMS-986337 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events, serious adverse events, and adverse events leading to discontinuation and Clinical laboratory values, vital signs, electrocardiograms, and physical examinations. Started Sep 2020; status: completed.